Allergenis

 A Significant Step Forward for Food Allergy Research - Check out the upcoming FDA workshop focused on biomarker-driven drug development. #foodallergies #diagnostics #parenting #FDA #biomarkers

Keep leading the way Peter Foley

Our StartEngine crowdfunding campaign is now closed. On behalf of the entire team at Allergenis, I am writing to express our deep appreciation and gratitude for any that have invested in or supported our company.   We hope you continue to follow and support us as we make significant strides towards developing innovative diagnostic solutions for individuals with food allergies. We want everyone with food allergies to #enjoylifeintheknow.   With deepest gratitude, Jim Garner, CEO of Allergenis #foodallergyawareness #diagnosticinnovation #healthcareinnovation #foodallergies

📣 Only a Few Hours Remaining to Invest in The Next BIG Thing in Food Allergies 📣 TODAY is the last day for you to become part owner in Allergenis and capitalize on the growing food allergy pandemic. 5 Reasons to Invest 1. Growing Prevalence of Food Allergies The prevalence of food allergies has been increasing over the past few decades, with an estimated 32 million Americans having food allergies. 2. Lack of Accurate Blood Tests Currently, as many as 60% of people are over diagnosed with food allergies, meaning they either avoid the allergen completely (unnecessarily) or perhaps pursuing an often expensive and time intensive immunotherapy treatments.  3. Innovative Solutions in Development There are several innovative solutions in development for food allergies, such as oral immunotherapy, patch therapy, which require new diagnostic tools. Investing in our technology now could lead to significant returns in the future. 4. Market Potential The global food allergy market has a current global valuation of $39B, and is expected to grow to $66B by the end of 2033. This presents a significant opportunity for investors looking to capitalize on the growing demand for food allergy solutions. 5. Social Impact Food allergies can be life-threatening, and investing in solutions that can help people diagnosis, manage and treat their allergies can have a significant impact on their quality of life. Invest ⤵ https://lnkd.in/e9u593RJ

Last 48 hours to Capitalize on New, Revolutionary Food Allergy Diagnostics Last chance to be part owner of Allergenis, and capitalize on food allergies. Allergenis is a company revolutionizing the way food allergies are diagnosed and managed, and we are doing it like no one else.  Our advisory team includes allergists from many of the major food allergy research centers in the U.S. including well known and respect allergists at places like Mount Sinai, Stanford, and Johns Hopkins to name a few.  Allergenis has an expert team of scientists and medical professionals who are dedicated to improving the diagnosis and treatment of food allergies. Our team includes board-certified allergists and immunologists, as well as experienced laboratory professionals who are committed to providing the highest quality of care to patients.   Allergenis is solving the food allergy problem like no one else, and their commitment to improving the lives of patients with food allergies is making a significant impact on the healthcare industry. Don't miss out on your (LAST CHANCE) opportunity to invest in Allergenis. ⏰ ⬇ https://lnkd.in/e9u593RJ

⏰ 72 hours left to invest in Allergenis ⏰ 3 Reasons to Invest TODAY - Don't miss your chance! Only 72 hours remaining to invest in the Allergenis current offering before the closing. See our 3 reasons to invest below and join our growing investor community! 1. AllerGenis' patent-protected food allergy diagnostic platform offers 93% accuracy, the highest rate for peanut allergy diagnosis compared to 60% accuracy of current blood tests. AllerGenis offers an in-market suite of peanut allergy tests and is in the advanced stages of development for additional food allergens. 2. AllerGenis is targeting the food allergy market with a current global valuation of $39B, expected to grow to $66B by the end of 2033. The Company has partnered with multiple global therapeutic companies generating revenue. It offers its tests through food allergist practices, including the largest allergy clinics in the U.S., as well as directly to consumers via a tele-medicine platform. 3. AllerGenis has previously raised $19 million, and its expert team of senior leaders have successfully developed and commercialized many diagnostic products currently in use as well as leading meaningful corporate exits. AllerGenis is a Mount Sinai Innovation Partner (MSIP) company. Invest TODAY! https://lnkd.in/e9u593RJ

👀 Have you seen us in Yahoo! Finance? 👀 Last 4 days to invest in food allergy diagnostics. Read more in Yahoo! Finance which features an article on our fundraising efforts. Article: https://lnkd.in/eVYbCR8X Invest: https://lnkd.in/e9u593RJ Last 4 days to invest.  Don't miss out, invest today! #startengine #crowdfunding #investing #foodandbeverageindustry #foodallergies #parenting

What inspired you to start AllerGenis and to continue to invest and champion the effort? - LESS THAN 4 DAYS TO INVEST! by John Simons - Managing Partner, Corporate Fuel& Founder, AllerGenis I am a parent.   Having seen some neighboring parents navigate their 7 year old daughter’s food allergies in 2004, I was witness to the burdens borne by food allergy families.  I imagined having stress about the ingredients in food served in our home and having to carry, not one, but two Epi Pens – in the event that the first injector didn’t work….. It frightened me.  The nightmare was a child’s anaphylaxis event and as the parent being unable to arrest the reaction and having the kid die in my arms…. I learned of Dr. Hugh Sampson’s work to develop better diagnostic tools for food allergies seven years ago.  And, given some work our associates had done with him, we knew he was on to something.   He was widely regarded and among the foremost allergy researchers in the world.  The existing diagnostic tools were just terrible, with the only available blood test providing incorrect guidance in 60% of all cases. Worthless, I thought.  Pharmaceutical companies, that might develop therapies to moderate or solve allergies were unable to attract patients to clinical trials because the only test that was available to test the patient’s allergy with certainty was a food challenge – purposely feeding a kid the allergen in increasing quantities until it induced a reaction and possibly anaphylaxis.  Barbaric.  So, no one wants to participate in clinical trials. And virtually no money is spent on food allergy therapeutics, yet tens of billions are spent on therapies for other immune response illnesses where better diagnostic tools exist.   Not only does Allergenis’ tests give clinicians and families better quality information about the status of their allergy – we will reduce the number of patients who think they have an allergy by some huge number.  We are also going to change the course of allergy drug development.  We are beginning to help pharmaceutical companies identify trial patients and will track the progress of clinical trials without food challenges – just by testing milliliters of blood. A predictable drug clinical trial path will now be clear and available.  This will unlock billions of drug development dollars at pharmaceutical companies anxious to address the very large food allergy market and ultimately lead to therapies that will make lives better and safer.  This is the promise of Allergenis. I hope you will join me in this endeavor. #Investing #FoodAllergies #Healthcare #Biotechnology #MedicalResearch #FoodAllergyTreatment #AllergyManagement #Innovation #InvestmentOpportunity #MedicalAdvancements #HealthcareInvestment #HealthTechInvestment #InvestmentTips #InvestorCommunity #Startups #Entrepreneurship #PatientCare #PersonalizedMedicine #InvestmentPotential #InvestmentOpportunity Invest today https://lnkd.in/e9u593RJ

In the News: New ‘Allergenis’ Test can Show Just How Allergic Your Kids Might be to Peanuts Less than a week to invest. Read the article: https://lnkd.in/gz5qJywH Invest: https://lnkd.in/e9u593RJ #investingnews #crowdsourcing #allergy #startengine #investors #diagnostics

What is the Allergenis secret sauce? 🤫 Why Allergenis is a good bet - Last 7 days to invest and capitalize on food allergy prevalence. We are a science and data-driven company.  Our core approach has been fundamental and follows a systems biology and data science model which makes good and common sense.   We worked with our scientific collaborators to measure protein parts which are key to an immune response to an allergen (the epitopes) in a precise and consistent manner.   We gathered well characterized food allergic cohorts from around the world, each confirmed with Oral Food Challenge. We integrated these data sets and generated more than 10,000 epitope maps (signatures); a total number of data points which exceed 1,300,000.   Then we used AI and machine learning enabled analytics to compare the epitope maps to Oral Food Challenge confirmed allergic status of each patient. The data yields predictive models and unique insights, including the rigorous validation of our in-market peanut allergy and nearing commercial readiness, cows milk allergy tests.  Moving forward, we will continue to leverage our biorepository which constitutes the largest globally OFC confirmed peanut and cow's milk allergic blood samples. Come join us and invest today. Last 7 days to invest on StartEngine https://lnkd.in/e9u593RJ #investing #startengine #crowdfunding #foodallergies #innovationinhealthcare #aiinnovation